Fig. 2

Parasite burden in infected human villous explants. The villous explants were infected with RH, ME49 or TgChBrUD1 (UD1) or TgChBrUD2 (UD2) (a) and treated with (b) azithromycin (1000 μg/mL) (AZ), (c) spiramycin (1000 μg/mL) (ESP) or (d) pyrimethamine (200 μg/mL) and sulfadiazine (150 μg/mL) (PS). The explants were collected and parasites were quantified at real-time PCR. The threshold cycle (Ct) value for each sample was compared to the standard control and the parasite quantity was analyzed. The data were presented in T. gondii DNA (100 ng/μl). Four placentas were used and four independent experiments were performed at least in duplicate. ^*Comparison between untreated/infected villous explants and infected/treated villous explants (Student’s t test, mean ± standard error of the mean (SEM), P < 0.05); ^#Comparison in relation to RH-infected villous explants; ^$Comparison in relation to ME49-infected villous explants; ^&Comparison in relation to UD1-infected villous explants; (ANOVA and Newman-Keuls multiple comparison test, mean ± standard error of the mean (SEM), P < 0.05)